Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
34,965,934
-
Share change
-
+4,371,885
-
Total reported value
-
$1,250,026,502
-
Put/Call ratio
-
193%
-
Price per share
-
$35.75
-
Number of holders
-
115
-
Value change
-
+$169,498,952
-
Number of buys
-
77
-
Number of sells
-
26
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2017
As of 31 Dec 2017,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
115 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,965,934 shares.
The largest 10 holders included
Essex Woodlands Management, Inc., WELLINGTON MANAGEMENT GROUP LLP, JPMORGAN CHASE & CO, FRANKLIN RESOURCES INC, NovaQuest Capital Management, L.L.C., BlackRock Inc., Bank of New York Mellon Corp, ArrowMark Colorado Holdings LLC, Vanguard Group Inc, and MILLENNIUM MANAGEMENT LLC.
This page lists
115
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.